Citation for published version (APA):
Valdes, A. M., Ravipati, S., Menni, C., Abhishek, A., Metrustry, S., Harris, J., ... Barrett, D. A. (2017). Association of the resolvin precursor 17-HDHA, but not D- or E-series resolvins, with heat pain sensitivity and osteoarthritis pain in humans. Scientific Reports, 7(1), [10748]. https://doi.org/10.1038/s41598-017-09516-3

Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the Research Portal

Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Association of the resolvin precursor 17-HDHA, but not D- or E-series resolvins, with heat pain sensitivity and osteoarthritis pain in humans

Ana M. Valdes1,2,3, Srinivasarao Ravipati4,6, Cristina Menni1, Abhishek Abhishek2, Sarah Metrustry1, Juliette Harris1, Ayrun Nessa5, Frances M. K. Williams1, Tim D. Spector1, Michael Doherty2, Victoria Chapman1,5,6 & David A. Barrett4*

Resolvins are omega-3 fatty acid derived potent bioactive lipids that resolve inflammation and modulate transient receptor potential channels. Exogenous administration of the resolvin precursor 17-HDHA shows a strong analgesic effect in animal models of osteoarthritis and acute inflammatory pain, but has not been studied in humans. Our aim was to assess the role of 17-HDHA and resolvins in heat pain sensitivity and in osteoarthritis pain in humans. Resolvins D1, D2, D3, D5, E1 and 17-HDHA, were measured by liquid chromatography-mass spectrometry and tested for association with heat pain thresholds in 250 healthy volunteers who had undergone quantitative sensory testing. Resolvins D1, D2 and 17-HDHA were then tested in 62 individuals affected with knee osteoarthritis and 52 age matched controls and tested for association with knee pain. Circulating levels of docosahexaenoic acid (DHA) were also measured. Levels of 17-HDHA, but not those of the other 5 resolvins tested, were associated with increased heat pain thresholds (beta = 0.075; 95% CI 0.024, 0.126; p < 0.0046). 17-HDHA was associated with lower pain scores in OA patients (beta = -0.41; 95% CI-0.69, -0.12; p < 0.005; adjusted for covariates) but not with radiographic osteoarthritis. The associations of 17-HDHA with heat pain sensitivity and osteoarthritis pain were independent of DHA levels.

Osteoarthritis (OA) is the fastest growing cause of chronic pain worldwide and is the commonest form of arthritis1. Pain is the predominant symptom of OA, which limits movement and causes disability2. It has long been recognised that the amount of pain people with OA experience is variable and only weakly correlated to the extent of joint damage, but the molecular basis underlying variation in OA pain is poorly understood3. It is well established pro-inflammatory agents are released into the joint and that synovitis is highly correlated to OA pain3, various cytokines and pro-inflammatory mediators are released in damaged tissue and induce a cascade of events that lead to peripheral sensitization4. These mediators accumulate in the joint as OA progresses4 and act to reduce threshold of joint nociceptors.

Chronic localised inflammatory pain is a feature of several chronic diseases5. The role of specialised pro-resolvin molecules in curtailing inflammatory responses has been demonstrated in cell systems and in vivo, with a fundamental role in the maintenance of tissue homeostasis6. The best characterised of these resolution molecules are the resolvins, which are oxygenated metabolites (or oxylipins) of omega-3 fatty acids7. The omega-3

1Department of Twin Research and Genetic Epidemiology, King’s College London, London, UK. 2Academic Rheumatology Clinical Sciences Building, Nottingham City Hospital, Hucknall Road, Nottingham, UK. 3National Institute of Health Research, Nottingham Biomedical Research Centre, Nottingham, UK. 4Centre for Analytical Bioscience, School of Pharmacy, University of Nottingham, NG7 2RD, Nottingham, UK. 5School of Life Sciences, University of Nottingham, Nottingham, UK. 6Arthritis Research UK Centre of Excellence for Pain, University of Nottingham, Nottingham, UK. Ana M. Valdes, Srinivasarao Ravipati, Victoria Chapman and David A. Barrett contributed equally to this work. Correspondence and requests for materials should be addressed to A.M.V. (email: Ana.Valdes@nottingham.ac.uk)
Fatty acids docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) are the precursors of D and E-series resolvins, respectively (Fig. 1). Resolvins suppress cytokine production and “resolve” the destructive inflammation by regulating leukocyte trafficking and clearance of inflammatory mediators (e.g. cytokines, prostaglandins and leukotrienes, growth factors and reactive oxygen species). D- and E-series resolvins inhibit several transient receptor potential (TRP) channels in vitro, which are essential to cutaneous thermal and pain sensation. Thus, in addition to their effect on inflammatory mediators, these compounds may play a direct role in nociception and specifically on thermal pain. Resolvins are also able to modulate N-Methyl-D-Aspartic acid (NMDA) receptors (Fig. 1). Phosphorylation of these receptors has been associated with hyperalgesia, neuropathic pain, and reduced functionality of opioid receptors.

Exogenous administration of resolvin E1 (RvE1) and resolvin D1 (RvD1) inhibits pain behaviour in animal models of acute inflammatory pain and in a model of chronic adjuvant-induced arthritis. RvD1 reduces mechanical allodynia and phosphorylation of NMDA receptors along with decreased cytokine expression in an animal model of chronic pancreatitis. Moreover, RvD1 has been shown to significantly attenuate arthritis severity and inflammation in a murine model of inflammatory arthritis but these protective actions are abolished in RvD1 receptor-deficient mice.

Resolvins are rapidly degraded in vivo resulting in a short biological half-life, but this limitation can be overcome by administration of precursors of the active molecules. 17-HDHA is a metabolite of the omega-3 fatty acid docosahexaenoic acid (DHA), and a precursor of D-series resolvins. Inhibitory effects of exogenous omega-3 fatty acids on pain and inflammation is evident in rheumatoid arthritis, however a randomised clinical trial of high vs low dose omega-3 administration failed to show an advantage of high omega-3 administration.

Exogenous 17-HDHA halted progression of pain behaviour in a surgical model of OA pain. However, 17-HDHA did not alter the extent of joint pathology, pointing to potential direct effects on sensory nerves or in the central nervous system and suggesting the therapeutic potential of this new class of analgesics for the treatment of OA pain. Thus, measurement of 17-HDHA may be useful in pinpointing the potential mechanisms of action of omega-3 on pain, which may reflect the effect of various D-series resolvins.

The potential role of resolvins and their metabolic precursors in human pain has yet to be explored, partly due to the lack of analytical methods for analysis of these lipids in biological tissues. Recent availability of authentic chemical standards for the resolvins and precursors has allowed the development of highly sensitive and specific liquid chromatography tandem mass spectrometry methods (LC-MS/MS) for their quantitative analysis. The aim of our study was to assess the role of 17-HDHA and resolvins in pain sensitivity, both in acute heat pain and in OA pain in humans. To address this aim, we have firstly investigated if the D-series resolvin precursor 17-HDHA is associated with thermal pain sensitivity in human volunteers, and whether any association with heat pain sensitivity can be explained by the levels of D- or E-series resolvins. Whether possible associations between 17-HDHA and pain sensitivity were reflective of omega-3 dietary intake was also established. Given the known role of inflammatory mediators in OA pain and potential link of pain responses to inflammation we also included in our model two omega-6 lipids, the prostaglandin precursor arachidonic acid (AA) and

---

**Figure 1.** Relationship between the omega-3 lipids measured in this study and other omega 3-fatty acid derived oxylipins. The assays did not distinguish chirality therefore compounds measure can be either the 17-S or 17-R enantiomers (e.g. 17-S-HDHA or 17-R-HDHA). Abbreviations: HEPE = Hydroxyeicosapentaenoic acid; RvE1 = resolvin E1; RvD(x) = resolvin Dx; PD1 = protectin D1; MaR1 = maresin 1; EPA = Eicosapentaenoic acid; DHA Docosahexaenoic acid; COX-2 + ASA = cyclooxygenase -2 and aspirin; HpDHA = hydroperoxy docosahexaenoic acid; HDHA = hydroxy docosahexaenoic acid; OxoDHA = oxodocosahexaenoic acid. TRP = transient potential receptor; NMDA = N-Methyl-D-Aspartic acid.
the leukotriene B4 recently reported to be involved in peripheral sensitization. We then asked if 17-HDHA or D-series resolvins were associated with knee pain intensity in individuals with knee OA, and whether any putative associations with OA pain are reflective of DHA serum levels. Finally, we assessed whether levels of 17-HDHA were associated with OA status comparing individuals affected with radiographic knee OA to OA free controls.

Subjects and Methods

Details on the study cohorts are included in the Supplementary section. All methods in this study were performed in accordance with relevant guidelines and regulations. Briefly:

Subjects. TwinsUK cohort. The TwinsUK registry contains twin volunteers recruited through national media campaigns and from other twin registers. The study was approved by the St Thomas’ Hospital research ethics committee, and all participants provided written informed consent. Participants be comparable to the age-matched general population singletons for a broad variety of medical and behavioural traits. Unselected twins (n = 2500) had been invited to attend St Thomas’ Hospital where they completed questionnaires gathering demographic information, clinical history and current medications. Exclusions included volunteers who had consumed analgesic medication within 12 hours of the study visit, and those with likely impaired upper limb neurology, e.g. known neuropathy, previous stroke or chemotherapy. Subjects having common painful conditions such as OA were not excluded. Participants underwent sensory testing individually as previously described.

The mean heat pain threshold (HPT) represents the temperature at which the sensation evoked by a thermal stimulus changes from feeling ‘hot’ to feeling ‘painful’ while the heat pain super threshold (HPST) records the temperature at which the sensation changes from “painful to unbearable”.

Bilateral knee radiographs of index knee or hip OA cases were obtained at two time points and scored for features of OA by a single observer using the Kellgren and Lawrence grade for the tibio-femoral and patella femoral compartments of each knee. Individuals also donated a blood sample from which plasma was extracted and stored for further analysis, and underwent a pain assessment. Participants completed a detailed nurse administered questionnaire on their symptoms and quality of life. Pain assessment was performed with the Western Ontario and McMaster Universities Arthritis Index (WOMAC) and plasma resolvins and DHA were adjusted for age, sex, BMI and K/L grade.

Laboratory analyses. Oxylipin and resolvin analysis method. The LC-MS/MS method used for eicosanoid analysis in human serum samples was based on the method previously developed adapted for the inclusion of resolvins and precursors as described in the Supplementary Section. All lipid measurements were quantitative and had precision values of better than ±15% and accuracies in the range 85–115% as determined from the analysis of calibration and QCs with each batch of samples.

Quantification was performed using fully extracted calibration standards for each of the analytes. Measured concentrations of 17-HDHA, Resolvin D2, Resolvin D1, Resolvin D3, Resolvin D5, Resolvin E1, AA, LTB4 were detectable in each sample and are corrected for sample volume where appropriately needed.

NMR Metabolomics. DHA and total omega-3 fatty acids were measured by Brainshake Ltd, Finland, (https://www.brainshake.fi/) from fasting serum or plasma samples using 500 MHz and 600 MHz proton nuclear magnetic resonance spectroscopy as previously described.

Statistical analysis. Concentrations of all resolvins, DHA and omega-3 fatty acids were log-transformed for analysis. The association between bioactive lipids and heat pain thresholds in TwinsUK was carried out using linear regressions using the log transformed HPT and HSPT as the outcome and adjusting for family relatedness, age and BMI. Additional models including circulating levels of DHA were also tested. Association between log transformed WOMAC pain scores and plasma resolvins and DHA were adjusted for age, sex, BMI and K/L grade or OA status. Analyses were performed using R version 3.0.1 (www.cran.org).

Results

The descriptive characteristics of the participants of both cohorts are summarized in Table 1. Plasma levels of 17-HDHA and D-series resolvins (OA case control) were lower than serum levels (TwinsUK cohort). The relationship between the omega-3 compounds measured is shown in Fig. 1.

Association with heat pain thresholds. We first tested if there was an association between the omega-3 derived bioactive lipids and heat pain sensitivity after adjustment for potential confounders. Of the lipids quantified, only 17-HDHA was associated with both HPST and HPT. None of the other D-series resolvins, or resolvin E1, were associated with pain sensitivity in this cohort. DHA and total omega – 3 levels were associated with HPST but not HPT (Table 2). Adjustment for circulating levels of DHA did not alter the association between 17-HDHA and heat pain thresholds (HPT and HPST) (Table 2).
Overall, DHA and omega-3 fatty acids were poorly associated with the various resolvins and this only achieved statistical significance for 17-HDHA and RvD2 (Supplementary Table 1). The pro-inflammatory mediator AA

| cohort       | TwinsUK | Nottingham controls | Nottingham knee OA |
|--------------|---------|---------------------|-------------------|
| n            | 250     | 52                  | 62                |
| sex F        | 100%    | 57.9%               | 61.1%             |
| age mean (SD)| 67.42 (8.08) | 67.78 (7.35) | 67.96 (8.62) |
| BMI kg/m² mean (SD) | 26.55 (4.40) | 28.24 (5.12) | 31.11 (6.43) |
| HPT °C mean (SD) | 46.26 (2.24) | 47.46 (1.84) |                   |
| HPST °C mean (SD) |             |                     |                   |
| K/L grade 0[1][2][3][4] | NA | 0.81[0.19] | 0.0 | 0.0 | 0.11 | 0.42 | 0.47 |
| WOMAC (0–20) pain score mean (SD) | NA | 2.17 (3.70) | 6.93 (4.37) | (4.37) |

| Serum bioactive lipids mean (SD) |
|----------------------------------|
| RvD1 (pmol/mL) | 0.042 (0.089) | NA | NA |
| RvD2 (pmol/mL) | 2.78 (3.34) | NA | NA |
| 17-HDHA (pmol/mL) | 162.32 (277.47) | NA | NA |
| RvD3 (pmol/mL) | 0.23 (0.53) | NA | NA |
| RvD5 (pmol/mL) | 0.39 (1.39) | NA | NA |
| RvE1 (pmol/mL) | 0.68 (2.32) | NA | NA |
| DHA (mmol/L) | 0.14 (0.05) | NA | NA |
| total omega 3 (mmol/L) | 0.43 (0.13) | NA | NA |
| AA (pmol/L) | 5531.10 (1949.4) | NA | NA |
| LTB4 (pmol/mL) | 79.44 (212.64) | NA | NA |

| Plasma bioactive lipids mean (SD) |
|----------------------------------|
| RvD1 (pmol/mL) | NA | 0.022 (0.026) | 0.22 (0.029) |
| RvD2 (pmol/mL) | NA | 1.24 (1.90) | 0.74 (0.86) |
| 17-HDHA (pmol/mL) | NA | 26.98 (18.56) | 25.40 (19.06) |
| DHA (mmol/L) | NA | 0.13 (0.02) | 0.13 (0.02) |
| total omega 3 (mmol/L) | NA | 0.34 (0.08) | 0.33 (0.07) |
| AA (pmol/L) | NA | 3012.6 (1553.6) | 3133.38 (1335.5) |
| LTB4 (pmol/mL) | NA | 14.86 (24.87) | 10.27 (10.93) |

Table 1. Descriptive characteristics of study cohorts. BMI = body mass index; HPT = heat pain threshold; HPST = heat pain super threshold; WOMAC = Western Ontario & McMaster Universities Osteoarthritis Index; K/L grade = Kellgren-Lawrence radiographic grade. RvDx = resolvin Dx; DHA = docohexadecanoic acid; AA = arachidonic acid. LTB4 = leukotriene B4.

Table 2. Association between serum resolvins and omega-3 fatty acids and heat pain thresholds (HPT) and heat pain super threshold (HPST) in the TwinsUK cohort. Association is expressed as the regression coefficient (beta) and the corresponding 95% confidence intervals (95% CI). The outcomes tested were HPT and HPST in the log scale, resolvin measures were also log transformed and regressions are adjusted for age, BMI and relatedness. ¹Model includes both DHA and 17-HDHA in addition to age, BMI and family relatedness. Nominally significant associations are highlighted in bold.
was negatively correlated with RvD2, RvD5, RvE1 and LTB4. LTB4 on the other hand was positively correlated with all the resolvins measured, except RvD2. However, we found no association between AA and LTB4 levels and heat pain thresholds. (Table 2).

We also assessed the correlations between the various resolvin compounds with each other, and with age and BMI (Supplementary Table 1). Although some resolvins were strongly correlated with each other, 17-HDHA was only significantly (and modestly) correlated with RvD2. The resolvins had no association with BMI, and only a weak correlation with age (Supplementary Table 1).

The distribution of the serum 17-HDHA levels in TwinsUK divided by categories of heat pain thresholds and heat pain super thresholds in the natural scale are shown in Fig. 2(A and B). Adjusting for the levels of LTB4 and AA had no effect on the association between 17-HDHA and HPT and HPST. The association between 17-HDHA and logHPT after adjusting for LTB4 and AA was beta = 0.0035 (95% CI 0.0008–0.0063, P = 0.0124), for logHPST it was beta = 0.0032 (95%CI 0.0010–0.0055; P = 0.005).

 Association of 17-HDHA with OA and OA pain. Since 17-HDHA was associated with pain sensitivity in humans, we hypothesized that this compound and not other D-series resolvins would be associated with OA pain. Herein we demonstrate that 17-HDHA, but not resolvin D1 nor D2, was associated with pain scores overall (Table 3). This was the case both in cases and controls adjusting for OA status and in OA cases only (unadjusted
The situation seen in animal models of rheumatoid arthritis, where D-series resolvins are strongly associated with omega-3/DHA. (Table 3) Finally, we adjusted results for the circulating levels of two omega-6 derived lipids that there may be two separate effects on pain and that the effect of 17-HDHA is not the one commonly attributed to omega-3 fatty acids. (AA and LTB4) and the association between 17-HDHA and OA pain remained similar (Table 3).

**Discussion**

In this study we show for the first time that 17-HDHA is associated with pain in humans, specifically with thermal pain sensitivity and the intensity of chronic pain. Previously, we have shown that exogenous systemic administration of 17-hydroxy docosahexaenoic acid (17-HDHA also abbreviated as 17-HDoHE) completely reversed pain sensitivity and the intensity of chronic pain. Previously, we have shown that exogenous systemic administration of 17-HDHA completely reversed pain sensitivity and the intensity of chronic pain. Previously, we have shown that exogenous systemic administration of 17-HDHA completely reversed pain sensitivity and the intensity of chronic pain. Previously, we have shown that exogenous systemic administration of 17-HDHA completely reversed pain sensitivity and the intensity of chronic pain. Previously, we have shown that exogenous systemic administration of 17-HDHA completely reversed pain sensitivity and the intensity of chronic pain. Previously, we have shown that exogenous systemic administration of 17-HDHA completely reversed pain sensitivity and the intensity of chronic pain. Previously, we have shown that exogenous systemic administration of 17-HDHA completely reversed pain sensitivity and the intensity of chronic pain. Previously, we have shown that exogenous systemic administration of 17-HDHA completely reversed pain sensitivity and the intensity of chronic pain. Previously, we have shown that exogenous systemic administration of 17-HDHA completely reversed pain sensitivity and the intensity of chronic pain. Previously, we have shown that exogenous systemic administration of 17-HDHA completely reversed pain sensitivity and the intensity of chronic pain. Previously, we have shown that exogenous systemic administration of 17-HDHA completely reversed pain sensitivity and the intensity of chronic pain. Previously, we have shown that exogenous systemic administration of 17-HDHA completely reversed pain sensitivity and the intensity of chronic pain. Previously, we have shown that exogenous systemic administration of 17-HDHA completely reversed pain sensitivity and the intensity of chronic pain. Previously, we have shown that exogenous systemic administration of 17-HDHA completely reversed pain sensitivity and the intensity of chronic pain. Previously, we have shown that exogenous systemic administration of 17-HDHA completely reversed pain sensitivity and the intensity of chronic pain. Previously, we have shown that exogenous systemic administration of 17-HDHA completely reversed pain sensitivity and the intensity of chronic pain. Previously, we have shown that exogenous systemic administration of 17-HDHA completely reversed pain sensitivity and the intensity of chronic pain. Previously, we have shown that exogenous systemic administration of 17-HDHA completely reversed pain sensitivity and the intensity of chronic pain. Previously, we have shown that exogenous systemic administration of 17-HDHA completely reversed pain sensitivity and the intensity of chronic pain. Previously, we have shown that exogenous systemic administration of 17-HDHA completely reversed pain sensitivity and the intensity of chronic pain. Previously, we have shown that exogenous systemic administration of 17-HDHA completely reversed pain sensitivity and the intensity of chronic pain. Previously, we have shown that exogenous systemic administration of 17-HDHA completely reversed pain sensitivity and the intensity of chronic pain. Previously, we have shown that exogenous systemic administration of 17-HDHA completely reversed pain sensitivity and the intensity of chronic pain. Previously, we have shown that exogenous systemic administration of 17-HDHA completely reversed pain sensitivity and the intensity of chronic pain. Previously, we have shown that exogenous systemic administration of 17-HDHA completely reversed pain sensitivity and the intensity of chronic pain. Previously, we have shown that exogenous systemic administration of 17-HDHA completely reversed pain sensitivity and the intensity of chronic pain. Previously, we have shown that exogenous systemic administration of 17-HDHA completely reversed pain sensitivity and the intensity of chronic pain. Previously, we have shown that exogenous systemic administration of 17-HDHA completely reversed pain sensitivity and the intensity of chronic pain. Previously, we have shown that exogenous systemic administration of 17-HDHA completely reversed pain sensitivity and the intensity of chronic pain. Previously, we have shown that exogenous systemic administration of 17-HDHA completely reversed pain sensitivity and the intensity of chronic pain. Previously, we have shown that exogenous systemic administration of 17-HDHA completely reversed pain sensitivity and the intensity of chronic pain. Previously, we have shown that exogenous systemic administration of 17-HDHA completely reversed pain sensitivity and the intensity of chronic pain. Previously, we have shown that exogenous systemic administration of 17-HDHA completely reversed pain sensitivity and the intensity of chronic pain. Previously, we have shown that exogenous systemic administration of 17-HDHA completely reversed pain sensitivity and the intensity of chronic pain. Previously, we have shown that exogenous systemic administration of 17-HDHA completely reversed pain sensitivity and the intensity of chronic pain. Previously, we have shown that exogenous systemic administration of 17-HDHA completely reversed pain sensitivity and the intensity of chronic pain. Previously, we have shown that exogenous systemic administration of 17-HDHA completely reversed pain sensitivity and the intensity of chronic pain. Previously, we have shown that exogenous systemic administration of 17-HDHA completely reversed pain sensitivity and the intensity of chronic pain. Previously, we have shown that exogenous systemic administration of 17-HDHA completely reversed pain sensitivity and the intensity of chronic pain. Previously, we have shown that exogenous systemic administration of 17-HDHA completely reversed pain sensitivity and the intensity of chronic pain. Previously, we have shown that exogenous systemic administration of 17-HDHA completely reversed pain sensitivity and the intensity of chronic pain. Previously, we have shown that exogenous systemic administration of 17-HDHA completely reversed pain sensitivity and the intensity of chronic pain. Previously, we have shown that exogenous systemic administration of 17-HDHA completely reversed pain sensitivity and the intensity of chronic pain. Previously, we have shown that exogenous systemic administration of 17-HDHA completely reversed pain sensitivity and the intensity of chronic pain. Previously, we have shown that exogenous systemic administration of 17-HDHA completely reversed pain sensitivity and the intensity of chronic pain. Previously, we have shown that exogenous systemic administration of 17-HDHA completely reversed pain sensitivity and the intensity of chronic pain. Previous...
Further studies are needed to understand the mechanisms by which 17-HDHA mediates an analgesic effect. One possibility is that higher levels of 17-HDHA lead to higher levels of 17-HpDHA, which in turn can be epoxidized into protectin D1 (Fig. 1). Although this mechanism could explain the human data it is harder to reconcile with the strong and long lasting analgesia produced by exogenous administration of 17-HDHA in rodent models of OA2. Another possibility is that the inhibitory effects of 17-HDHA are all due to RvD4 (not measured in our study but known to modulate receptors involved in nociception), or that 17-HDHA may be directly involved in modulating pain and pain sensitivity.

Transient receptor potential (TRP) family of ligand-gated ion channels, in particular TRPV1, have an established role in thermal sensitivity7 and contributes to pain in OA (e.g. ref. 27). Previous studies have reported effects of the resolvins on TRP channels. In an in vitro dorsal root ganglia (sensory nerve) preparation RvD1 suppressed the activity of various TRP channels (TRPA1, TRPV3 and TRPV4), but not TRPV1 and TRPV2 activity. TRPV1 activity was however inhibited by RvE1. D- and E-series resolvins also modulate NMDA receptors in animal models23 and reduce mechanical allodynia and pain behaviour in models of chronic pancreatitis31. However, in our human study neither RvD1 nor RvE1 are associated with thermal pain thresholds. To our knowledge the role of 17-HDHA on TRP channels has not been reported in the literature12, therefore it is feasible that 17-HDHA may have direct effects on TRP function. Additional mechanisms by which 17-HDHA may exert an effect on pain includes a metabolite of 17-HDHA, 17-oxoDHA which is an agonist at peroxisome proliferator activated receptors (PPAR) alpha and gamma28. Interestingly, PPAR-alpha and gamma agonists have anti-nociceptive effects in a rat model of irritable bowel syndrome via a nitric-oxide mediated mechanism29.

Our study highlights for the first time the potential of 17-HDHA as a biomarker for pain and provides a platform for a potential new approach to analgesia. Nevertheless, to separate 17-S and 17-R isomers of the various compounds would enable further mechanistic insight. For example, levels of RvD2 could be reflecting more activity via the 17-5 (15 lipoxigenase mediated) pathway whereas levels of 17-HDHA may be reflecting the 17-R (P450 or COX-2+ aspirin or statin mediated) pathway. We did not test other DHA derived bioactive lipids such as maresins and protectins which are likely to have an effect on pain responses (Fig. 1). Although we did not measure EPA levels, we did measure an EPA derived resolvin (RvE1) and found no association with heat pain thresholds.

One of the benefits of our study is the demonstration that 17-HDHA can be measured both in plasma and serum samples in humans. However, we do report large differences between the mean values of 17-HDHA and the two D-series resolvins measured in plasma (OA case control study) and serum samples. Although serum and heparinized plasma specimens are considered equivalent for some assays, differences in results between sample types have been reported for many chemistry analytes30. The higher levels in serum are consistent with what is known about resolvin and resolvin precursors (i.e. the presence of platelets generates higher concentration of these lipids31). It is important to note that the twin cohort in which we have tested the relationship between resolvins were only females. However, the heat pain thresholds data have been used successfully in other studies and have been shown to be heritable32. Finally, the OA cohort was only assessed for the standard OA pain instrument (WOMAC) and not for pain thresholds.

In conclusion, we have shown that 17-HDHA is associated with pain in humans, specifically with heat pain sensitivity and the intensity of chronic pain, which is unlikely to be due to its being a precursor to other D-series resolvins. 17-HDHA is known to be anti-nociceptive in models of OA pain and our novel finding that 17-HDHA can modulate pain responses in humans suggest that exogenous administration of 17-HDHA in humans may also be analgesic. Further work is needed to understand the anti-nociceptive mechanism of 17-HDHA which will shed light on pathways suitable for therapeutic intervention in OA pain.

References
1. Glyn-Jones, S. et al. Osteoarthritis. Lancet 365, 376–387 (2015).
2. Perrot, S. Osteoarthritis pain. Best Pract Res Clin Rheumatol 29, 90–97 (2015).
3. Berenbaum, F. Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!). Osteoarthritis Cartilage 21, 16–21 (2013).
4. Krustev, E., Rioux, D. & McDougall, J. J. Mechanisms and Mediators That Drive Arthritis Pain. Curr Osteoporos Rep 13, 216–224 (2015).
5. Ji, R. R., Xu, Z. Z., Strichartz, G. & Serhan, C. N. Emerging roles of resolvins in the resolution of inflammation and pain. Trends Neurosci 34, 599–609 (2011).
6. Serhan, C. N. Pro-resolving lipid mediators are leads for resolution physiology. Nature 510, 92–101 (2014).
7. Schweke, R. C., Marcon, R., Bento, A. F. & Calixto, J. B. EPA- and DHA-derived resolvins’ actions in inflammatory bowel disease. Eur J Pharmacol 785, 156–164 (2016).
8. Bang, S., Yoo, S., Yang, T. J., Cho, H. & Hwang, S. W. 17(R)-resolvin D1 specifically inhibits transient receptor potential ion channel vanilloid 3 leading to peripheral antinociception. Br J Pharmacol 165, 683–692 (2012).
9. Mickle, A. D., Shepherd, A. J. & Mohapatra, D. P. Nociceptive TRP Channels: Sensory Detectors and Transducers in Multiple Pain Pathologies. Pharmaceuticals (Basel) 9 (2016).
10. Cottright, D. N. & Szallasi, A. TRP channels and cytokines expression in the thoracic spinal dorsal horn. BMC Neurosci 15, 1736–1749 (2009).
11. Quan-Xin, F. et al. Resolvin D1 reverses chronic pancreatitis-induced mechanical allodynia, phosphorylation of NMDA receptors, and cytokines expression in the thoracic spinal dorsal horn. BMC Gastroenterol 12, 148 (2012).
12. Choi, G. & Hwang, S. W. Modulation of the Activities of Neuronal Ion Channels by Fatty Acid-Derived Pro-Resolvants. Front Physiol 7, 533 (2016).
13. Yoo, S., Lim, J. Y. & Hwang, S. W. Resolvins: Endogenously Generated Potent Painkilling Substances and their Therapeutic Perspectives. Curr Neuropharmaco. 11, 664–676 (2013).
14. Norling, L. V. et al. Proresolving and cartilage-protective actions of resolvin D1 in inflammatory arthritis. JCI Insight 1, e85922 (2016).
15. Lee, Y. H., Bae, S. C. & Song, G. G. Omega-3 polyunsaturated fatty acids and the treatment of rheumatoid arthritis: a meta-analysis. Arch Med Res 43, 356–362 (2012).
16. Hill, C. L. et al. Fish oil in knee osteoarthritis: a randomised clinical trial of low dose versus high dose. Ann Rheum Dis 75, 23–29 (2016).
17. Huang, J. et al. Targeting the D Series Resolvin Receptor System for the Treatment of Osteoarthritis Pain. *Arthritis Rheumatol* **69**, 996–1008 (2017).
18. Colas, R. A., Shinohara, M., Dalli, J., Chiang, N. & Serhan, C. N. Identification and signature profiles for pro-resolving and inflammatory lipid mediators in human tissue. *Am J Physiol Cell Physiol* **307**, C39–54 (2014).
19. Zinn, S. et al. The leukotriene B4 receptors BLT1 and BLT2 form an antagonistic sensitizing system in peripheral sensory neurons. *J Biol Chem* **292**, 6123–6134 (2017).
20. Moayyeri, A., Hammont, C. J., Valdes, A. M. & Specter, T. D. Cohort Profile: TwinsUK and healthy ageing twin study. *Int J Epidemiol* **42**, 76–85 (2013).
21. Williams, F. M. et al. Genes contributing to pain sensitivity in the normal population: an exome sequencing study. *PLoS Genet* **8**, e1003095 (2012).
22. Kellgren, J. H., Lawrence, J. S. & Bier, F. Genetic Factors in Generalized Osteo-Arthrosis. *Ann Rheum Dis* **22**, 237–255 (1963).
23. Bellamy, N. & Buchanan, W. W. Outcome measurement in osteoarthritis clinical trials: the case for standardisation. *Clin Rheumatol* **3**, 293–303 (1984).
24. Zhang, J. H. et al. Quantitative profiling of epoxyeicosatrienoic, hydroxyeicosatetraenoic, and dihydroxyeicosatetraenoic acids in human intrauterine tissues using liquid chromatography/electrospray ionization tandem mass spectrometry. *Anal Biochem* **365**, 40–51 (2007).
25. Wong, A. et al. Simultaneous tissue profiling of eicosanoid and endocannabinoid lipid families in a rat model of osteoarthritis. *J Lipid Res* **55**, 1902–1913 (2014).
26. Soininen, P., Kangas, A. J., Wurtz, P., Suna, T. & Ala-Korpela, M. Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics. *Circ Cardiovasc Genet* **8**, 192–206 (2015).
27. Valdes, A. M. et al. The Ile858Val TRPV1 variant is involved in risk of painful knee osteoarthritis. *Ann Rheum Dis* **70**, 1556–1561 (2011).
28. Egawa, D., Itoh, T., Akiyama, Y., Saito, T. & Yamamoto, K. 17-OxoDHA is a PPARalpha/gamma Dual Covalent Modifier and Agonist. *ACS Chem Biol* **11**, 2447–2455 (2016).
29. Paragomi, P. et al. Antinociceptive and anti diarrheal effects of pioglitazone in a rat model of diarrhoea-predominant irritable bowel syndrome: role of nitric oxide. *Clin Exp Pharmacol Physiol* **41**, 118–126 (2014).
30. Miles, R. R., Roberts, R. E., Putnam, A. R. & Roberts, W. L. Comparison of serum and heparinized plasma samples for measurement of chemistry analytes. *Clin Chem* **50**, 1704–1706 (2004).
31. Lannan, K. L., Spinelli, S. L., Blumberg, N. & Phipps, R. P. Maresin 1 induces a novel pro-resolving phenotype in human platelets. *J Thromb Haemost* **15**, 802–813 (2017).

**Acknowledgements**

This work was supported by Arthritis Research UK (grant number 18769), the Medical Research Council (grant number MR/M016560/1), and the D - BOARD Consortium funded by European Commission Framework 7 Programme (EU FP7; HEALTH.2012.2.4.5-2, project number 305815, Novel Diagnostics and Biomarkers for Early Identification of Chronic Inflammatory Joint Diseases)); TwinsUK receives funding from the Wellcome Trust European Community’s Seventh Framework Programme (FP7/2007–2013 to Twins UK); the National Institute for Health Research (NIHR) Clinical Research Facility at Guy’s & St Thomas’ NHS Foundation Trust and NIHR Biomedical Research Centre based at Guy’s and St Thomas’ NHS Foundation Trust and King’s College London. FW receives funding from the EU FP7 project Pain_omics. We thank Petros Poussinis for his technical assistance during the MS measurements.

**Author Contributions**

A.M.V., V.C. and A.A. wrote the main manuscript text, A.M.V. carried out statistical analyses, S.R. carried out the oxylipin measurements, C.M., A.M.V., P.P. and S.R. performed data Q.C., J.H. and N.S. performed quantitative sensory testing analyses, F.M.K.W. supervised the Q.S.T. and twin recruitment, S.M. liaised sample transfer, D.B., A.M.V. and T.D.S. performed data QA, M.D. supervised the O.A. patient collection and X ray grading, A.M.V., T.D.S., D.B., F.M.K.W. and V.C. developed the study design, All authors reviewed the manuscript.

**Additional Information**

Supplementary information accompanies this paper at doi:10.1038/s41598-017-09516-3

**Competing Interests:** The authors declare that they have no competing interests.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.